4
Changes in Ownership
ARROWHEAD PHARMACEUTICALS, INC. Filed Acc 0001628280-24-003097
Chief Executive Officer sold 57,499 shares at an average $32.35 ($1,860,019)
- Chief Executive Officer acquired 57,499 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Anzalone Christopher Richard Chief Executive Officer | 2024-01-31 | Option exercise 10b5-1 | +57,499 | $14.54 | $836,035 | 3,772,547 | D |
| Anzalone Christopher Richard Chief Executive Officer | 2024-01-31 | Sale 10b5-1 | −37,769 | $32.16 | $1,214,651 | 3,734,778 | D |
| Anzalone Christopher Richard Chief Executive Officer | 2024-01-31 | Sale 10b5-1 | −19,730 | $32.71 | $645,368 | 3,715,048 | D |
| Derivatives | |||||||
| Anzalone Christopher Richard Chief Executive Officer | 2024-01-31 | Option exercise · Stock Option (right to buy) 10b5-1 | −57,499 | 351,726 | D | ||
| Open-market sales · 57,499 sh · avg $32.35 · $1,860,019 | |||||||
Loading xslF345X05/wk-form4_1706912729.xml…